tetano
Editor, Senior Moderator
BMC Infect Dis
. 2022 Nov 9;22(1):831.
doi: 10.1186/s12879-022-07808-2.
Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
Chuancai Xu[SUP] #[/SUP][SUP] 1 [/SUP], Zhisong He[SUP] #[/SUP][SUP] 2 [/SUP], Wei Lei[SUP] #[/SUP][SUP] 1 [/SUP], Li Chen[SUP] 3 [/SUP], Dan Shen[SUP] 1 [/SUP], Xiaofei Wang[SUP] 1 [/SUP], Deyu Xu[SUP] 4 [/SUP], Ying Xu[SUP] 5 [/SUP], Jian'an Huang[SUP] 6 [/SUP]
Affiliations
Abstract
Background: At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown.
Methods: We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People's Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients.
Results: The median duration of viral RNA shedding was shorter in the FV (12 [IQR, 9.5-14] days) and PV (13 [IQR, 9-16.75] days) groups than in the UV group (15 [IQR, 11.75-17.25] days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co [IQR, 2.08-63.59] and 0.3 S/co [IQR, 0.05-2.29], respectively) and PV (0.68 S/co [IQR, 0.14-28.69] and 0.12 S/co [0.03-5.23], respectively) groups than in the UV group (0.06 S/co [IQR, 0.03-0.47] and 0.04 S/co [IQR, 0.02-0.07]) (adjusted P < 0.001 and adjusted P = 0.008, respectively).
Conclusions: Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection.
Keywords: Breakthrough infection; Inactivated vaccine; SARS-CoV-2; SARS-CoV-2-specific IgG; SARS-CoV-2-specific IgM; Viral RNA shedding.
. 2022 Nov 9;22(1):831.
doi: 10.1186/s12879-022-07808-2.
Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
Chuancai Xu[SUP] #[/SUP][SUP] 1 [/SUP], Zhisong He[SUP] #[/SUP][SUP] 2 [/SUP], Wei Lei[SUP] #[/SUP][SUP] 1 [/SUP], Li Chen[SUP] 3 [/SUP], Dan Shen[SUP] 1 [/SUP], Xiaofei Wang[SUP] 1 [/SUP], Deyu Xu[SUP] 4 [/SUP], Ying Xu[SUP] 5 [/SUP], Jian'an Huang[SUP] 6 [/SUP]
Affiliations
- PMID: 36352356
- DOI: 10.1186/s12879-022-07808-2
Abstract
Background: At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown.
Methods: We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People's Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients.
Results: The median duration of viral RNA shedding was shorter in the FV (12 [IQR, 9.5-14] days) and PV (13 [IQR, 9-16.75] days) groups than in the UV group (15 [IQR, 11.75-17.25] days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co [IQR, 2.08-63.59] and 0.3 S/co [IQR, 0.05-2.29], respectively) and PV (0.68 S/co [IQR, 0.14-28.69] and 0.12 S/co [0.03-5.23], respectively) groups than in the UV group (0.06 S/co [IQR, 0.03-0.47] and 0.04 S/co [IQR, 0.02-0.07]) (adjusted P < 0.001 and adjusted P = 0.008, respectively).
Conclusions: Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection.
Keywords: Breakthrough infection; Inactivated vaccine; SARS-CoV-2; SARS-CoV-2-specific IgG; SARS-CoV-2-specific IgM; Viral RNA shedding.